Cargando…

Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway

BACKGROUND: During the 2009-2010 pandemic in Norway, 12 513 laboratory-confirmed cases of pandemic influenza A(H1N1)pdm09, were reported to the Norwegian Surveillance System for Communicable Diseases (MSIS). 2.2 million persons (45% of the population) were vaccinated with an AS03-adjuvanted monovale...

Descripción completa

Detalles Bibliográficos
Autores principales: Guzmán Herrador, Bernardo Rafael, Aavitsland, Preben, Feiring, Berit, Riise Bergsaker, Marianne A, Borgen, Katrine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3344681/
https://www.ncbi.nlm.nih.gov/pubmed/22429643
http://dx.doi.org/10.1186/1471-2334-12-63
_version_ 1782232047249522688
author Guzmán Herrador, Bernardo Rafael
Aavitsland, Preben
Feiring, Berit
Riise Bergsaker, Marianne A
Borgen, Katrine
author_facet Guzmán Herrador, Bernardo Rafael
Aavitsland, Preben
Feiring, Berit
Riise Bergsaker, Marianne A
Borgen, Katrine
author_sort Guzmán Herrador, Bernardo Rafael
collection PubMed
description BACKGROUND: During the 2009-2010 pandemic in Norway, 12 513 laboratory-confirmed cases of pandemic influenza A(H1N1)pdm09, were reported to the Norwegian Surveillance System for Communicable Diseases (MSIS). 2.2 million persons (45% of the population) were vaccinated with an AS03-adjuvanted monovalent vaccine during the pandemic. Most of them were registered in the Norwegian Immunisation Registry (SYSVAK). Based on these registries, we aimed at estimating the vaccine effectiveness (VE) and describing vaccine failures during the pandemic in Norway, in order to evaluate the role of the vaccine as a preventive measure during the pandemic. METHODS: We conducted a population-based retrospective cohort study, linking MSIS and SYSVAK with pandemic influenza vaccination as exposure and laboratory-confirmed pandemic influenza as outcome. We measured VE by week and defined two thresholds for immunity; eight and 15 days after vaccination. RESULTS: The weekly VE ranged from 77% to 96% when considering 15 days or more after vaccination as the threshold of immunity and from 73% to 94% when considering eight days or more. Overall, 157 individuals contracted pandemic influenza eight or more days after vaccination (8.4/100,000 vaccinated), of these 58 had onset 15 days or more after vaccination (3.0/100,000 vaccinated). Most of the vaccine failures occurred during the first weeks of the vaccination campaign. More than 30% of the vaccine failures were found in people below 10 years of age. CONCLUSIONS: Having available health registries with data regarding cases of specific disease and vaccination makes it feasible to estimate VE in a simple and rapid way. VE was high regardless the immunity threshold chosen. We encourage public health authorities in other countries to set up such registries. It is also important to consider including information on underlying diseases in registries already existing, in order to make it feasible to conduct more complete VE estimations.
format Online
Article
Text
id pubmed-3344681
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33446812012-05-07 Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway Guzmán Herrador, Bernardo Rafael Aavitsland, Preben Feiring, Berit Riise Bergsaker, Marianne A Borgen, Katrine BMC Infect Dis Research Article BACKGROUND: During the 2009-2010 pandemic in Norway, 12 513 laboratory-confirmed cases of pandemic influenza A(H1N1)pdm09, were reported to the Norwegian Surveillance System for Communicable Diseases (MSIS). 2.2 million persons (45% of the population) were vaccinated with an AS03-adjuvanted monovalent vaccine during the pandemic. Most of them were registered in the Norwegian Immunisation Registry (SYSVAK). Based on these registries, we aimed at estimating the vaccine effectiveness (VE) and describing vaccine failures during the pandemic in Norway, in order to evaluate the role of the vaccine as a preventive measure during the pandemic. METHODS: We conducted a population-based retrospective cohort study, linking MSIS and SYSVAK with pandemic influenza vaccination as exposure and laboratory-confirmed pandemic influenza as outcome. We measured VE by week and defined two thresholds for immunity; eight and 15 days after vaccination. RESULTS: The weekly VE ranged from 77% to 96% when considering 15 days or more after vaccination as the threshold of immunity and from 73% to 94% when considering eight days or more. Overall, 157 individuals contracted pandemic influenza eight or more days after vaccination (8.4/100,000 vaccinated), of these 58 had onset 15 days or more after vaccination (3.0/100,000 vaccinated). Most of the vaccine failures occurred during the first weeks of the vaccination campaign. More than 30% of the vaccine failures were found in people below 10 years of age. CONCLUSIONS: Having available health registries with data regarding cases of specific disease and vaccination makes it feasible to estimate VE in a simple and rapid way. VE was high regardless the immunity threshold chosen. We encourage public health authorities in other countries to set up such registries. It is also important to consider including information on underlying diseases in registries already existing, in order to make it feasible to conduct more complete VE estimations. BioMed Central 2012-03-20 /pmc/articles/PMC3344681/ /pubmed/22429643 http://dx.doi.org/10.1186/1471-2334-12-63 Text en Copyright ©2012 Herrador et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Guzmán Herrador, Bernardo Rafael
Aavitsland, Preben
Feiring, Berit
Riise Bergsaker, Marianne A
Borgen, Katrine
Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway
title Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway
title_full Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway
title_fullStr Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway
title_full_unstemmed Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway
title_short Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway
title_sort usefulness of health registries when estimating vaccine effectiveness during the influenza a(h1n1)pdm09 pandemic in norway
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3344681/
https://www.ncbi.nlm.nih.gov/pubmed/22429643
http://dx.doi.org/10.1186/1471-2334-12-63
work_keys_str_mv AT guzmanherradorbernardorafael usefulnessofhealthregistrieswhenestimatingvaccineeffectivenessduringtheinfluenzaah1n1pdm09pandemicinnorway
AT aavitslandpreben usefulnessofhealthregistrieswhenestimatingvaccineeffectivenessduringtheinfluenzaah1n1pdm09pandemicinnorway
AT feiringberit usefulnessofhealthregistrieswhenestimatingvaccineeffectivenessduringtheinfluenzaah1n1pdm09pandemicinnorway
AT riisebergsakermariannea usefulnessofhealthregistrieswhenestimatingvaccineeffectivenessduringtheinfluenzaah1n1pdm09pandemicinnorway
AT borgenkatrine usefulnessofhealthregistrieswhenestimatingvaccineeffectivenessduringtheinfluenzaah1n1pdm09pandemicinnorway